AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVR) was the target of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 59,500 shares, a decrease of 14.0% from the January 15th total of 69,200 shares. Approximately 2.6% of the company’s shares are sold short. Based on an average daily trading volume, of 26,100 shares, the short-interest ratio is currently 2.3 days.

Hedge Funds Weigh In On AlloVir

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its position in shares of AlloVir by 0.8% during the fourth quarter. Northern Trust Corp now owns 159,685 shares of the company’s stock worth $67,000 after purchasing an additional 1,267 shares during the last quarter. Jane Street Group LLC raised its stake in AlloVir by 47.8% during the fourth quarter. Jane Street Group LLC now owns 123,159 shares of the company’s stock worth $52,000 after acquiring an additional 39,808 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of AlloVir in the fourth quarter valued at approximately $25,000. Finally, Gilead Sciences Inc. acquired a new stake in shares of AlloVir in the fourth quarter valued at approximately $6,987,000. 66.05% of the stock is owned by hedge funds and other institutional investors.

AlloVir Stock Up 0.2 %

ALVR stock opened at $9.90 on Friday. The company has a market cap of $49.80 million, a price-to-earnings ratio of -0.49 and a beta of 0.65. The business has a fifty day simple moving average of $10.10 and a 200-day simple moving average of $14.58. AlloVir has a 52 week low of $7.96 and a 52 week high of $24.15.

About AlloVir

AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.